Synapse - MRD response-driven phase I/II study for newly diagnosed multiple myeloma patients using higher doses of twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone

MRD response-driven phase I/II study for newly diagnosed multiple myeloma patients using higher doses of twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone Meeting Abstract

Authors:	Korde, N.; Mailankody, S.; Smith, E. L.; Lendvai, N.; Hassoun, H.; Lesokhin, A.; Hultcrantz, M.; Chung, D. J.; Shah, G. L.; Koehne, G.; Landau, H.; Roshal, M.; Dogan, A.; Giralt, S. A.; Mastey, D.; Evancha, N.; Devlin, S. M.; Landgren, O.
Abstract Title:	MRD response-driven phase I/II study for newly diagnosed multiple myeloma patients using higher doses of twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone
Meeting Title:	59th Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	130
Issue:	Suppl. 1
Meeting Dates:	2017 Dec 9-12
Meeting Location:	Atlanta, GA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2017-12-07
Language:	English
ACCESSION:	WOS:000432419700333
PROVIDER:	wos
DOI:	10.1182/blood.V130.Suppl_1.3133.3133
Notes:	Meeting Abstract: 3133 -- Source: Wos